Makki Alaa A, Elderderi Suha, Massot Victor, Respaud Renaud, Byrne Hugh J, Tauber Clovis, Bertrand Dominique, Mohammed Elhadi, Chourpa Igor, Bonnier Franck
Université de Tours, EA 6295 Nanomédicaments et Nanosondes, 31 Avenue Monge, 37200, Tours, France; University of Gezira, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, P.O. Box 20, 21111, Wad Madani, Sudan.
CHU de Tours, Unité de Biopharmacie Clinique Oncologique, Pharmacie, France.
Talanta. 2021 Jun 1;228:122137. doi: 10.1016/j.talanta.2021.122137. Epub 2021 Feb 9.
Analytical Quality Control (AQC) in centralised preparation units of oncology centers is a common procedure relying on the identification and quantification of the prepared chemotherapeutic solutions for safe intravenous administration to patients. Although the use of Raman spectroscopy for AQC has gained much interest, in most applications it remains coupled to a flow injection analyser (FIA) requiring withdrawal of the solution for analysis. In addition to current needs for more rapid and cost-effective analysis, the risk of exposure of clinical staff to the toxic molecules during daily handling is a serious concern to address. Raman spectroscopic analysis, for instance by Confocal Raman Microscopy (CRM), could enable direct analysis (non-invasive) for AQC directly in infusion bags. In this study, 3 anticancer drugs, methotrexate (MTX), 5-fluorouracil (5-FU) and gemcitabine (GEM) have been selected to highlight the potential of CRM for withdrawal free analysis. Solutions corresponding to the clinical range of each drug were prepared in 5% glucose and data was collected from infusion bags placed under the Raman microscope. Firstly, 100% discrimination has been obtained by Partial Least Squares Discriminant Analysis (PLS-DA) confirming that the identification of drugs can be performed. Secondly, using Partial Least Squares Regression (PLSR), quantitative analysis was performed with mean % error of predicted concentrations of respectively 3.31%, 5.54% and 8.60% for MTX, 5-FU and GEM. These results are in accordance with the 15% acceptance criteria used for the current clinical standard technique, FIA, and the Limits of Detection for all drugs were determined to be substantially lower than the administered range, thus highlighting the potential of confocal Raman spectroscopy for direct analysis of chemotherapeutic solutions.
肿瘤中心集中配制单元的分析质量控制(AQC)是一种常见程序,依赖于对配制的化疗溶液进行识别和定量,以安全地静脉注射给患者。尽管拉曼光谱用于AQC已引起广泛关注,但在大多数应用中,它仍与流动注射分析仪(FIA)联用,需要抽取溶液进行分析。除了当前对更快速、更具成本效益分析的需求外,临床工作人员在日常操作中接触有毒分子的风险也是一个需要解决的严重问题。例如,通过共聚焦拉曼显微镜(CRM)进行的拉曼光谱分析可以直接在输液袋中进行AQC的直接分析(非侵入性)。在本研究中,选择了3种抗癌药物,甲氨蝶呤(MTX)、5-氟尿嘧啶(5-FU)和吉西他滨(GEM),以突出CRM进行免抽取分析的潜力。在5%葡萄糖中制备了对应于每种药物临床范围的溶液,并从置于拉曼显微镜下的输液袋中收集数据。首先,通过偏最小二乘判别分析(PLS-DA)获得了100%的判别率,证实了药物的识别是可行的。其次,使用偏最小二乘回归(PLSR)进行定量分析,MTX、5-FU和GEM预测浓度的平均百分比误差分别为3.31%、5.54%和8.60%。这些结果符合当前临床标准技术FIA使用的15%验收标准,并且所有药物的检测限均确定远低于给药范围,从而突出了共聚焦拉曼光谱直接分析化疗溶液的潜力。